JSM Activity #376

This is the preliminary program for the 2003 Joint Statistical Meetings in San Francisco, California. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 2-5, 2003); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions.

To View the Program:
You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time.

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

Back to main JSM 2003 Program page
Legend: = Applied Session, = Theme Session, = Presenter
Hotels: H = Hilton San Francisco, R = Reniassance Parc Hotel 55, N = Nikko San Francisco
Add To My Program
376 Applied Session Wed, 8/6/03, 10:30 AM - 12:20 PM H-Continental Ballroom 2 & 3
Clinical Trial Safety and Adverse Events - Contributed - Papers
Biopharmaceutical Section
Chair(s): Brenda L. Gaydos, Eli Lilly & Company
     10:35 AM   Early Trials to Establish Safety with Respect to Rare, Serious Adverse Events — Alfred H. Balch, Novartis Pharmaceuticals
     10:50 AM   Assessment of Adverse Events in Titration Studies — Balakrishna S. Hosmane, Northern Illinois University; Yonghang (Fred) Yang, Aventis Pharmaceuticals, Inc.
     11:05 AM   Evaluating Hazard Rate of Serious Adverse Events in Long-Term Clinical Trials — Rafia Bhore, Food and Drug Administration; Mohammad F. Huque, Food and Drug Administration
     11:20 AM   Using a Nonlinear Mixed-Effects Model to Adjust the QT Interval for Heart Rate — Juan (Joanne) Zhang, Food and Drug Administration; Stella G. Machado, Food and Drug Administration; Sam Haidar, Food and Drug Administration
     11:35 AM   Statistical Analysis of Cardiac Allograft Vasculopathy Using Intravascular Ultrasound — Kamal H. Abeywickrama, Novartis Pharmaceuticals
     11:50 AM   An Evaluation of the Relationship Between Acute and Delayed Efficacy in Two Regimens for Preventing Chemotherapy Induced Nausea and Vomiting: An Oral NK1 Antagonist (Aprepitant) Regimen and a Standard Therapy Regimen — Guoguang Ma, Merck & Company; Alexandra Carides
     12:05 PM   Identification of Prognostic Factors: A Case Study in a Pancreatic Cancer Trial — Youn C. Park, Johnson & Johnson Pharmaceutical Research and Development, LLC; Ramin B. Arani, Johnson & Johnson Pharmaceutical Research and Development, LLC
 

JSM 2003 For information, contact meetings@amstat.org or phone (703) 684-1221. If you have questions about the Continuing Education program, please contact the Education Department.
Revised March 2003